Smith & Nephew is a global medical technology company founded in 1856, headquartered in Hull, England. The company designs and manufactures technology focused on the repair, regeneration, and replacement of soft and hard tissue. It operates in more than 100 countries and employs over 18,000 people, serving millions of patients annually. Smith & Nephew is listed on both the London Stock Exchange, as a FTSE 100 constituent, and the New York Stock Exchange.
The company's technical expertise spans orthopaedics, sports medicine, ENT (ear, nose, and throat), advanced wound management, robotics-assisted surgery, and bioinductive implants. Its product portfolio includes the PICO negative pressure wound therapy system, the CORI Surgical System for robotics-assisted surgery, and the REGENETEN Bioinductive Implant.
Legal professionals at Smith & Nephew operate within a multinational, publicly traded healthcare and medical technology environment. The company's regulatory footprint spans multiple jurisdictions given its global operations across more than 100 countries and its dual listing on major stock exchanges.
